Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances

Research output: Contribution to journalArticle

Authors

Colleges, School and Institutes

External organisations

  • Centre for Liver Research, NIHR Birmingham Liver Biomedical Research Unit, University of Birmingham, Birmingham B15 2TT, UK.

Abstract

In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and immunological mechanistic insights.

Details

Original languageEnglish
Pages (from-to)76-78
Number of pages3
JournalNature Reviews. Gastroenterology & Hepatology
Volume14
Issue number2
Early online date11 Jan 2017
Publication statusPublished - Feb 2017

Keywords

  • obeticholic acid, Primary biliary cholangitis, cholangiocytes, Cholestatic liver disease, biliary